 This study uses a novel oral agent apremilast that modulates multiple anti-inflammatory pathways through targeted phosphodiesterase type IV PDE4 inhibition decreased expression of dermatitis. Apremilast has pharmacodynamic properties with a potential therapeutic benefit for treating inflammatory autoimmune disorders that involve elevated serum cytokine levels, including Atopic Dermatitis AD and Allergic Contact Dermatitis ACD. 